Patents by Inventor Jeffrey Wayne Clough

Jeffrey Wayne Clough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
    Patent number: 8314093
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: November 20, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jeffrey Wayne Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 8304422
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: November 6, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 8299087
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: October 30, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Arvinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • 2,4-pyrimidinediamine compounds and their uses
    Patent number: 8188276
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: May 29, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G Payan, Susan Molineaux, Sasha J Holland, Jeffrey Wayne Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7947698
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 24, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20110082146
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: December 13, 2010
    Publication date: April 7, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20110027856
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: October 11, 2010
    Publication date: February 3, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Arvinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7834024
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: November 16, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Avinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
    Patent number: 7659280
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: February 9, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jeffrey Wayne Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20080279867
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: March 21, 2008
    Publication date: November 13, 2008
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20080260754
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 23, 2008
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Avinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper